Immunotherapy breaches low-sugar dieting of tumor Treg cells

Clarissa Campbell; Alexander Y Rudensky

doi:10.1016/j.cmet.2021.04.010

Immunotherapy breaches low-sugar dieting of tumor Treg cells

Cell Metab. 2021 May 4;33(5):851-852. doi: 10.1016/j.cmet.2021.04.010.

Authors

Clarissa Campbell¹, Alexander Y Rudensky²

Affiliations

¹ Howard Hughes Medical Institute and Immunology Program, Sloan Kettering Institute, and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: [email protected].
² Howard Hughes Medical Institute and Immunology Program, Sloan Kettering Institute, and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

PMID: 33951469
DOI: 10.1016/j.cmet.2021.04.010

Abstract

Glycolysis supports effector T cell function but is detrimental to the immunosuppressive activity of regulatory T cells. In a recent issue of Nature, two papers address a role for glucose and lactate availability within the tumor microenvironment for the balance of pro- and anti-tumoral effects of T cells and the efficacy of neoadjuvant cancer immunotherapy.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immunotherapy
Neoplasms* / therapy
Sugars
T-Lymphocytes, Regulatory*
Tumor Microenvironment

Substances

Sugars